Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by QT Testing Services Experts (US)

Analysis of: Ablynx Reports Positive Phase I Results for Its Anti-Thrombotic Nanobody(R), ALX-0081 (www.pipelinereview.com)
vWF is one of a number of attractive antiplatelet targets which include P2Y112, GIIb/IIIa, to name a few. Currently Medicines Company's Cangrelor, a small molecule against P2Y12 is quite far along in development.  In addition, Archemix just published results of its Phase I trial with its anti-vWF...
Analysis of: ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 (www.pipelinereview.com)
The IDEAL anticoagulant is: 1. Efficacious - Prevents thrombosis 2. Safe - Low risk of bleeding 3. Titratable - Offers predictable, adjustable, therapeutic effect tailorable to individual patient needs 4. Reversible - Can be actively TURNED OFF if/when necessary (or "dialed down") 5. Convenient - Bolus...
Analysis of: Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds (boston.stockgroup.com)
Factor IX is also a promising target, as it is unique in carrying the coagulation signal from the site of injury with tissue factor activation, to the surface of platelets, where propagation and amplification of coagulation actually occur. REG1 (Regado Biosciences), a highly specific, actively reversible...
Richard Anthony, PhD, Board member
Richard Anthony, PhD, Board member
Janus Pharmaceuticals, Inc.
Analysis of: Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease (www.pipelinereview.com)
Viagra (sildenafil) a same a PDE-5 same  class compound as SLx-2101 has shown efficacy for Raynaud's by significantly reducing the frequency and duration of Raynaud attacks and improved capillary flow velocity by 400%, according to a study led by Roland Fries, M.D and published online...
Analysis of: Over-The-Counter Weight Loss Drug Approved (abclocal.go.com)
does it work?  Is the AE profile translatable to a larger population? 
Analysis of: Vegf Trap-Eye Phase 2 Wet Amd Results Reported At Arvo Annual Meeting (www.pipelinereview.com)
VEGF Trap could be better than Lucentis or Avastin in that it can neutralize VEGF isoforms that Lucentis or Avastin cannot neutralize.
May 18, 2007
AMD Treatments
Analysis of: Ranibizumab, PDT combination successfully treats neovascular AMD (www.osnsupersite.com)
Ranibizumab and PDT are both approved treatments and hence are interesting to see how they compare in combination. 
April 30, 2007
not yet
Analysis of: Major phase 3 program planned for new antiplatelet drug (www.theheart.org)
The only available oral inhibitor of thrombin is warfarin which is a nightmare compound to deal with from a level and DDI standpoint.   
April 13, 2007
EPO for Heart Failure
Analysis of: F.D.A. Warning Is Issued on Anemia Drugs’ Overuse (www.nytimes.com)
•Anemia has been implicated as a major factor affecting outcomes in chronic heart failure. •This FDA action will, therefore, also likely abort attempts to extend use of recombinant hematopoeitic agents to treatment of chronic heart failure.
April 11, 2007
Best yet to come
Analysis of: New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses (newsroom.lilly.com)
This is but the first of a slew of new agents aimed at various stages of platelet function (aggregation and adhesion), not just activation.

Page : 11 to 10 of 10

Analytics


Generated at 2009-01-09T13:00:20.343